

THE LANCET

Haematology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Bonaventure A, Harewood R, Stiller CA, et al, and the CONCORD Working Group. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of data including 89 828 children from 198 registries in 53 countries. *Lancet Haematol* 2017; published online April 11. [http://dx.doi.org/10.1016/S2352-3026\(17\)30052-2](http://dx.doi.org/10.1016/S2352-3026(17)30052-2).

Supplementary appendix to:

Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries

Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Piñeros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, Allemani C, and the CONCORD Working Group

CONCORD Working Group	p2
Web-table 1: Definition of leukaemia sub-types, based on morphology codes from the International Classification of Diseases for Oncology, third edition (ICD-O-3) ¹ , with groupings from the International Classification of Childhood Cancer, third edition ²	p5
Web-table 2: Precursor-cell lymphoid leukaemia (ICCC-3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis	p6
Web-table 3: Acute myeloid leukaemia (ICCC-3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis	p15

CONCORD Working Group

Africa—Algeria: S Bouzbid (Registre du Cancer d'Annaba); M Hamdi-Chérif*, Z Zaidi (Registre du Cancer de Sétif); **Gambia:** E Bah, R Swaminathan (National Cancer Registry); **Lesotho:** SH Nortje (Children's Haematology Oncology Clinics - Lesotho); **Libya:** MM El Mistiri (Benghazi Cancer Registry); **Mali:** S Bayo, B Malle (Kankou Moussa University); **Mauritius:** SS Manraj, R Sewpaul-Sungkur (Mauritius Cancer Registry); **Nigeria:** A Fabowale, OJ Ogunbiyi* (Ibadan Cancer Registry); **South Africa:** D Bradshaw, NIM Somdyala (Eastern Cape Province Cancer Registry); DC Stefan (Umtata University); **Sudan:** M Abdel-Rahman (University of Khartoum); **Tunisia:** L Jaidane, M Mokni (Registre du Cancer du Centre Tunisien).

America (Central and South)—Argentina: I Kumcher, F Moreno (National Childhood Cancer Registry – National Cancer Institute); MS González, EA Laura (Registro Regional de Tumores del Sur de la Provincia de Buenos Aires); SB Espinola, GH Calabrano (Registro Poblacional de Tumores de la Provincia del Chubut); B Carballo Quintero, R Fita (Registro Provincial de Tumores de Córdoba); DA Garcilazo, PL Giacciani (Entre Rios Cancer Registry); MC Diumenjo, WD Laspada (Registro Provincial de Tumores de Mendoza); MA Green, MF Lanza (Registro de Cáncer de Santa Fe); SG Ibañez (Cancer Registry of Tierra del Fuego Province); **Brazil:** CA Lima, E Lobo de Oliveira (Registro de Câncer de Base Populacional de Aracaju); C Daniel, C Scanduzzi (Cancer Registry of Distrito Federal); PCF De Souza, CD Melo (Registro de Câncer de Base Populacional de Cuiabá); K Del Pino, C Laporte (Registro de Curitiba); MP Curado, JC de Oliveira (Registro de Goiânia); CLA Veneziano, DB Veneziano (Registro de Câncer de Base Populacional de Jahu); TS Alexandre, AS Verdugo (Registro de Câncer de São Paulo); G Azevedo e Silva* (University of Rio de Janeiro); **Chile:** JC Galaz, JA Moya (Registro Poblacional de Câncer Region de Antofagasta); DA Herrmann, S Vargas (Registro Poblacional Region de Los Rios); **Colombia:** VM Herrera, CJ Uribe (Registro Poblacional de Câncer Area Metropolitana de Bucaramanga); LE Bravo (Cali Cancer Registry); NE Arias-Ortiz (Registro Poblacional de Câncer de Manizales); DM Jurado, MC Yépez (Registro Poblacional de Câncer del Municipio de Pasto); **Cuba:** YH Galán, P Torres (Registro Nacional de Câncer de Cuba); **Ecuador:** F Martínez-Reyes, ML Pérez-Meza (Cuenca Tumor Registry); L Jaramillo, R Quinto (Guayaquil Cancer Registry); P Cueva, JG Yépez (Quito Cancer Registry); **Puerto Rico:** CR Torres-Cintrón, G Tortolero-Luna (Puerto Rico Central Cancer Registry); **Uruguay:** R Alonso, E Barrios (Registro Nacional de Câncer).

America (North)—Canada: C Nikiforuk, L Shack (Alberta Cancer Registry); AJ Coldman, RR Woods (British Columbia Cancer Registry); G Noonan, D Turner* (Manitoba Cancer Registry); E Kumar, B Zhang (New Brunswick Provincial Cancer Registry); FR McCrate, S Ryan (Newfoundland and Labrador Cancer Registry); H Hannah (Northwest Territories Cancer Registry); RAD Dewar, M MacIntyre (Nova Scotia Surveillance and Epidemiology Unit); A Lalany, M Ruta (Nunavut Department of Health and Social Services); L Marrett, DE Nishri* (Ontario Cancer Registry); C McClure, KA Vriends (Prince Edward Island Cancer Registry); C Bertrand, R Louchini (Registre Québécois du Cancer); KI Robb, H Stuart-Panko (Saskatchewan Cancer Registry); S Demers, S Wright (Yukon Government); **USA:** JT George, X Shen (Alabama Statewide Cancer Registry); JT Brockhouse, DK O'Brien (Alaska Cancer Registry); KC Ward (Georgia Comprehensive Cancer Registry; Metropolitan Atlanta Registry); L Almon (Metropolitan Atlanta Registry); J Bates (California State Cancer Registry); R Rycroft (Colorado Central Cancer Registry); L Mueller, C Phillips (Connecticut Tumor Registry); H Brown, B Cromartie (Delaware Cancer Registry); AG Schwartz, F Vigneau (Metropolitan Detroit Cancer Surveillance System); JA MacKinnon, B Wohler (Florida Cancer Data System); AR Bayakly (Georgia Comprehensive Cancer Registry); CA Clarke, SL Glaser (Greater Bay Area Cancer Registry); D West (Cancer Registry of Greater California); MD Green, BY Hernandez (Hawaii Tumor Registry); CJ Johnson, D Jozwik (Cancer Data Registry of Idaho); ME Charlton, CF Lynch (State Health Registry of Iowa); B Huang, TC Tucker* (Kentucky Cancer Registry); D Deapen, L Liu (Los Angeles Cancer Surveillance Program); MC Hsieh, XC Wu (Louisiana Tumor Registry); K Stern (Maryland Cancer Registry); ST Gershman, RC Knowlton (Massachusetts Cancer Registry); J Alverson, GE Copeland (Michigan State Cancer Surveillance Program); DB Rogers (Mississippi Cancer Registry); D Lemons, LL Williamson (Montana Central Tumor Registry); M Hood (Nebraska Cancer Registry); GM Hosain, JR Rees (New Hampshire State Cancer Registry); KS Pawlish, A Stroup (New Jersey State Cancer Registry); C Key, C Wiggins (New Mexico Tumor Registry); AR Kahn, MJ Schymura (New York State Cancer Registry); G Leung, C Rao (North Carolina Central Cancer Registry); L Giljahn, B Warther (Ohio Cancer Incidence Surveillance System); A Pate (Oklahoma Central Cancer Registry); M Patil, SS Schubert (Oregon State Cancer Registry); JJ Rubertone, SJ Slack (Pennsylvania Cancer Registry); JP Fulton, DL Rousseau (Rhode Island Cancer Registry); TA Janes, SM Schwartz (Seattle Cancer Surveillance System); SW Bolick, DM Hurley (South Carolina Central Cancer Registry); J Richards, MA Whiteside (Tennessee Cancer Registry); LM Nogueira (Texas Cancer Registry); K Herget, C Sweeney (Utah Cancer Registry); J Martin, S Wang (Virginia Cancer Registry); DG Harrelson, MB Keitheri Cheteri (Washington State Cancer Registry); S Farley, AG Hudson (West Virginia Cancer Registry); R Borchers, L Stephenson (Wisconsin Department of Health Services); JR

Espinoza (Wyoming Cancer Surveillance Program); HK Weir* (Centers for Disease Control and Prevention); BK Edwards* (National Cancer Institute).

Asia—China: N Wang, L Yang (Beijing Cancer Registry); JS Chen (Changle City Cancer Registry); GH Song (Cixian Cancer Registry); XP Gu (Dafeng County Center for Disease Control and Prevention); P Zhang (Dalian Centers for Disease Prevention and Control); HM Ge (Donghai County Center for Disease Prevention and Control); DL Zhao (Feicheng County); JH Zhang (Ganyu Center for Disease Prevention and Control); FD Zhu (Guanyun Cancer Registry); JG Tang (Haimen Cancer Registry); Y Shen (Haining City Cancer Registry); J Wang (Jianhu Cancer Registry); QL Li (Jiashan County Cancer Registry); XP Yang (Jintan Cancer Registry); J Dong, W Li (Lianyungang Center for Disease Prevention and Control); LP Cheng (Henan Province Central Cancer Registry); JG Chen (Qidong County Cancer Registry); QH Huang (Sihui Cancer Registry); SQ Huang (Taixing Cancer Registry); GP Guo (Cancer Institute of Yangzhong City); K Wei (Zhongshan City Cancer Registry); WQ Chen*, H Zeng (National Central Cancer Registry China); **Cyprus:** AV Demetriou, P Pavlou (Cyprus Cancer Registry); **Hong Kong:** WK Mang, KC Ngan (Hong Kong Cancer Registry); **India:** R Swaminathan (Chennai Cancer Registry); AC Katak, M Krishnatraya (Guwahati Cancer Registry); PA Jayalekshmi, P Sebastian (Karunagappally Cancer Registry); SD Sapkota, Y Verma (Population Based Cancer Registry, Sikkim); A Nandakumar* (National Centre for Disease Informatics and Research; National Cancer Registry Programme); **Indonesia:** E Suzanna (Jakarta Cancer Registry); **Israel:** L Keinan-Boker, BG Silverman (Israel National Cancer Registry); **Japan:** H Ito, H Nakagawa (Aichi Cancer Registry); M Hattori, Y Kaizaki (Fukui Cancer Registry); H Sugiyama, M Utada (Hiroshima Prefecture Cancer Registry); K Katayama, H Narimatsu (Kanagawa Cancer Registry); S Kanemura (Miyagi Prefectural Cancer Registry); T Koike (Niigata Prefecture Cancer Registry); I Miyashiro (Osaka Cancer Registry); M Yoshii (Saga Prefectural Cancer Registry); I Oki (Tochigi Prefectural Cancer Registry); A Shibata (Yamagata Cancer Registry); T Matsuda* (National Cancer Center); **Jordan:** O Nimri (Jordan National Cancer Registry); **Malaysia:** A Ab Manan, N Bhoo Pathy (Penang Cancer Registry); **Mongolia:** O Chimedsuren, S Tuvshingerel (Cancer Registry of Mongolia); **Qatar:** AHM Al Khater, MM El Mistiri (Qatar Cancer Registry); **Saudi Arabia:** H Al-Eid (Saudi National Cancer Registry); **South Korea:** KW Jung, YJ Won (Korea Central Cancer Registry); **Taiwan:** CJ Chiang, MS Lai (Taiwan Cancer Registry); **Thailand:** K Suwanrungruang, S Wiangnon (Khon Kaen Provincial Registry); K Daoprasert, D Pongnikorn (Lampang Cancer Registry); SL Geater, H Sriplung (Songkhla Cancer Registry); **Turkey:** S Eser, CI Yakut (Izmir Cancer Registry).

Europe—Austria: M Hackl (Austrian National Cancer Registry); H Mühlböck, W Oberaigner (Tyrol Cancer Registry); **Belarus:** AA Zborovskaya (Belarus Childhood Cancer Subregistry); OV Aleinikova (Belarusian Research Center for Pediatric Oncology, Hematology and Immunology); **Belgium:** K Henau, L Van Eycken (Belgian Cancer Registry); **Bulgaria:** N Dimitrova, Z Valerianova (Bulgarian National Cancer Registry); **Croatia:** M Šekerija (Croatian National Cancer Registry); **Czech Republic:** M Zvolský (Czech National Cancer Registry); **Denmark:** G Engholm, H Storm* (Danish Cancer Society); **Estonia:** K Innos, M Mägi (Estonian Cancer Registry); **Finland:** N Malila, K Seppä (Cancer Society of Finland); **France:** J Jégu, M Velten (Bas-Rhin General Cancer Registry); E Cornet, X Troussard (Registre Régional des Hémopathies Malignes de Basse Normandie); AM Bouvier, J Faivre (Burgundy Digestive Cancer Registry); AV Guizard (Calvados General Cancer Registry); V Bouvier, G Launoy (Calvados Digestive Cancer Registry); P Arveux (Côte-d'Or Gynaecologic Cancer Registry); M Maynadié, M Mounier (Côte-d'Or Haematopoietic Malignancies Registry); E Fournier, AS Woronoff (Doubs and Belfort Territory General Cancer Registry); M Daoulas (Finistère Cancer Registry); J Clavel (National Registry of Childhood Haematopoietic Malignancies); S Le Guyader-Peyrou, A Monnereau (Gironde Haematopoietic Malignancies Registry); B Trétarre (Hérault General Cancer Registry); M Colonna (Isère General Cancer Registry); A Cowppli-Bony, F Molinié (Loire-Atlantique-Vendée Cancer Registry); S Bara, D Degré (Manche General Cancer Registry); O Ganry, B Lapôtre-Ledoux (Somme General Cancer Registry); P Grosclaude (Tarn General Cancer Registry); J Estève (Hospices Civils de Lyon); F Bray*, M Piñeros* (International Agency for Research on Cancer); F Sassi (Organisation for Economic Co-operation and Development); **Germany:** R Stabenow (Common Cancer Registry of the Federal States); A Eberle (Bremen Cancer Registry); C Erb, A Nennecke (Hamburg Cancer Registry); J Kieschke, E Sirri (Epidemiological Cancer Registry of Lower Saxony); H Kajueter (North Rhine Westphalia Cancer Registry); K Emrich, SR Zeissig (Rhineland Palatinate Cancer Registry); B Holleczeck (Saarland Cancer Registry); N Eisemann, A Katalinic (Schleswig-Holstein Cancer Registry); H Brenner (German Cancer Research Center); **Gibraltar:** RA Asquez, V Kumar (Gibraltar Cancer Registry); **Iceland:** EJ Ólafsdóttir, L Tryggvadóttir (Icelandic Cancer Registry); **Ireland:** H Comber, PM Walsh (National Cancer Registry); H Sundseth* (European Institute of Women's Health); **Italy:** E Devigili, G Mazzoleni (Registro Tumori Alto Adige); A Giacomini (Registro Tumori Biella); F Bella, M Castaing (Integrated Cancer Registry of Catania-Messina-Siracusa-Enna); A Suter (Registro Tumori Catanzaro); G Gola (Registro Tumori della Provincia di Como); S Ferretti (Registro Tumori della Provincia di Ferrara); D Serraino, A Zucchetto (Registro Tumori del Friuli Venezia Giulia); R Lillini, M Vercelli (Registro Tumori Regione Liguria); S Busco, F Pannozzo (Registro Tumori della Provincia di Latina); S Vitarelli (Registro Tumori

della Provincia di Macerata); P Ricci (Registro Tumori Mantova); C Pascucci (Registro Tumori Marche Childhood); M Autelitano (Registro Tumori Milano); C Cirilli, M Federico (Registro Tumori della Provincia di Modena); M Fusco, MF Vitale (Registro Tumori della ASL Napoli 3 sud); M Usala (Nuoro Cancer Registry); R Cusimano, W Mazzucco (Registro Tumori di Palermo e Provincia); M Michiara, P Sgargi (Registro Tumori della Provincia di Parma); MM Maule, C Sacerdote (Piedmont Childhood Cancer Registry); R Tumino (Registro Tumori della Provincia di Ragusa); E Di Felice, M Vicentini (Registro Tumori Reggio Emilia); F Falcini (Registro Tumori della Romagna); L Cremona (Registro Tumori Salerno); M Budroni, R Cesaraccio (Registro Tumori della Provincia di Sassari); ML Contrino, F Tisano (Registro Tumori Siracusa); AC Fanetti, S Maspero (Registro Tumori della Provincia di Sondrio); G Candela, T Scuderi (Registro Tumori Trapani); MA Gentilini, S Piffer (Registro Tumori Trento); S Rosso, L Sacchetto (Registro Tumori Piemonte Città di Torino); A Caldarella (Registro Tumori della Regione Toscana); F La Rosa, F Stracci (Registro Tumori Umbro di Popolazione); P Contiero, G Tagliabue (Registro Tumori Lombardia, Provincia di Varese); AP Dei Tos, M Zorzi (Registro Tumori Veneto); R Zanetti* (International Association of Cancer Registries); P Baili, F Berrino*, G Gatta, M Sant* (Fondazione IRCCS Istituto Nazionale dei Tumori); R Capocaccia*, R De Angelis (National Centre for Epidemiology); **Latvia**: E Liepina, A Maurina (Latvian Cancer Registry); **Lithuania**: G Smailyte (Lithuanian Cancer Registry); **Malta**: D Agius, N Calleja (Malta National Cancer Registry); **Netherlands**: S Siesling, O Visser (Comprehensive Cancer Centre of the Netherlands); **Norway**: S Larønningen, B Møller (The Cancer Registry of Norway); **Poland**: A Dyzmann-Sroka, M Trojanowski (Greater Poland Cancer Registry); S Góźdź, R Mężyk (Cancer Registry of Kielce); M Grądalska-Lampart, AU Radziszewska (Podkarpackie Cancer Registry); JA Didkowska, U Wojciechowska (National Cancer Registry); J Błaszczyk, K Kępska (Lower Silesian Cancer Registry); M Bielska-Lasota, K Kwiatkowska (National Institute of Public Health - NIH); **Portugal**: G Forjaz, RA Rego (Registo Oncológico Regional dos Açores); J Bastos, MA Silva (Registo Oncológico Regional do Centro); L Antunes, MJ Bento (Registo Oncológico Regional do Norte); A Mayer-da-Silva, A Miranda (Registo Oncológico Regional do Sul); **Romania**: D Coza, AI Todescu (Cancer Institute I. Chiricuta); **Russian Federation**: MY Valkov (Arkhangelsk Regional Cancer Registry); **Slovakia**: J Adamcik, C Safaei Diba (National Cancer Registry of Slovakia); **Slovenia**: M Primic-Žakelj, T Žagar (Cancer Registry of Republic of Slovenia); J Stare (University of Ljubljana); **Spain**: E Almar, A Mateos (Registro de Cáncer de Albacete); JR Quirós (Registro de Tumores del Principado de Asturias); J Bidaurrezaga, N Larrañaga (Basque Country Cancer Registry); JM Díaz García, AI Marcos (Registro de Cáncer de Cuenca); R Marcos-Gragera, ML Vilardell Gil (Registre de Càncer de Girona); E Molina, MJ Sánchez (Registro de Cáncer de Granada); P Franch Sureda, M Ramos Montserrat (Mallorca Cancer Registry); MD Chirlaque, C Navarro (Murcia Cancer Registry); EE Ardanaz, CC Moreno-Iribas (Registro de Cáncer de Navarra); R Fernández-Delgado, R Peris-Bonet (Registro Español de Tumores Infantiles (RETI-SEHOP)); J Galceran (Tarragona Cancer Registry); **Sweden**: S Khan, M Lambe (Swedish Cancer Registry); **Switzerland**: B Camey (Registre Fribourgeois des Tumeurs); C Bouchardy, M Usel (Geneva Cancer Registry); SM Ess (Cancer Registry Grisons and Glarus); C Herrmann (Cancer Registry Grisons and Glarus; Cancer Registry of St Gallen-Appenzell); JL Bulliard, M Maspoli-Conconi (Registre Neuchâtelois des Tumeurs); H Frick (Cancer Registry of St Gallen-Appenzell); CE Kuehni, M Schindler (Swiss Childhood Cancer Registry); A Bordoni, A Spitale (Registro Tumori Cantone Ticino); A Chiolerio, I Konzelmann (Registre Valaisan des Tumeurs); SI Dehler, KL Matthes (Krebsregister der Kantone Zürich und Zug); **United Kingdom**: J Rashbass, CA Stiller* (Public Health England); D Fitzpatrick, A Gavin (Northern Ireland Cancer Registry); F Bannon (Queens University, Belfast); RJ Black, DH Brewster (Scottish Cancer Registry); DW Huws, C White (Welsh Cancer Intelligence & Surveillance Unit); P Finan (Leeds General Infirmary); C Allemani*, A Bonaventure, H Carreira, MP Coleman*, V Di Carlo, R Harewood, K Liu, M Matz, L Montel, M Nikšić, B Rachet*, N Sanz, D Spika (London School of Hygiene & Tropical Medicine); R Stephens* (National Cancer Research Institute, London); M Peake (University of Leicester), MFG Murphy (University of Oxford).

Oceania—Australia: E Chalker, L Newman (Australian Capital Territory Cancer Registry); D Baker, MJ Soeberg (NSW Cancer Registry); J Aitken, C Scott (Queensland Cancer Registry); BC Stokes, A Venn (Tasmanian Cancer Registry); H Farrugia, GG Giles (Victorian Cancer Registry); T Threlfall (Western Australian Cancer Registry); D Currow*, H You (Cancer Institute NSW); **New Zealand**: J Hendrix, C Lewis (New Zealand Cancer Registry).

*CONCORD Steering Committee

Web-table 1

Definition of leukaemia sub-types, based on morphology codes from the International Classification of Diseases for Oncology, third edition (ICD-O-3)¹, with groupings from the International Classification of Childhood Cancer, third edition²

ICD-O-3 morphology code	Label (main title)	ICCC-3 subgroup (if any)
Lymphoid leukaemias (group Ia)		
9835	Precursor cell lymphoblastic leukaemia, NOS	Precursor-cell
9836	Precursor B-cell lymphoblastic leukaemia	Precursor-cell
9837	Precursor T-cell lymphoblastic leukaemia	Precursor-cell
9823	B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma	Mature B-cell
9826	Burkitt cell leukaemia	Mature B-cell
9832	Prolymphocytic leukaemia, NOS	Mature B-cell
9833	Prolymphocytic leukaemia, B-cell type	Mature B-cell
9940	Hairy cell leukaemia	Mature B-cell
9827	Adult T-cell leukaemia/lymphoma (HTLV-1 positive)	Mature T-cell and NK cell
9831	T-cell large granular lymphocytic leukaemia	Mature T-cell and NK cell
9834	Prolymphocytic leukaemia, T-cell type	Mature T-cell and NK cell
9948	Aggressive NK-cell leukaemia	Mature T-cell and NK cell
9820	Lymphoid leukaemia, NOS	Lymphoid leukaemia, NOS
Acute myeloid leukaemias (group Ib)		
9840	Acute myeloid leukaemia, M6 type	
9861	Acute myeloid leukaemia, NOS	
9866	Acute promyelocytic leukaemia, t(15;17) (q22;q11-12)	
9867	Acute myelomonocytic leukaemia	
9870	Acute basophilic leukaemia	
9871	Acute myeloid leukaemia with abnormal marrow eosinophils	
9872	Acute myeloid leukaemia, minimal differentiation	
9873	Acute myeloid leukaemia without maturation	
9874	Acute myeloid leukaemia with maturation	
9891	Acute monocytic leukaemia	
9895	Acute myeloid leukaemia with multilineage dysplasia	
9896	Acute myeloid leukaemia, t(8;21)(q22;q22)	
9897	Acute myeloid leukaemia, 11q23 abnormalities	
9910	Acute megakaryoblastic leukaemia	
9920	Therapy-related acute myeloid leukaemia, NOS	
9931	Acute panmyelosis with myelofibrosis	
Unspecified and other specified leukaemias (group Ic)		
9800	Leukaemia, NOS	
9801	Acute leukaemia, NOS	
9805	Acute biphenotypic leukaemia	
9860	Myeloid leukaemia, NOS	
9930	Myeloid sarcoma	

References

1. Fritz AG, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM, Whelan SL, editors. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva: World Health Organization; 2000.
2. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer* 2005; **103**: 1457-67.

Web-table 2

Precursor-cell lymphoid leukaemia (ICCC-3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Net survival estimates by sex were age-standardised where possible. Estimates in italics are not age-standardised

* National coverage – the data are derived from a population-based cancer registry (registries) covering the entire country

^M Estimate based on merging data for 2 (or all 3) calendar periods

^R Age-standardised estimate computed by pooling two age-specific estimates and re-estimation

[§] Estimate judged as less reliable

‡ Korea: Republic of Korea; Russia: Russian Federation

Web-table 2: Precursor-cell lymphoid leukaemia (ICCC3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
AFRICA																		
Algerian registries																		
2000-2004	1			3			6			9			11	56·5 [§]	25·6 - 87·3	8		
2005-2009				7			5			5			9			8		
Lesotho *																		
1995-2009				5			13	25·3 ^M	0·7 - 49·9	4			13	43·6 ^M	14·8 - 72·3	9		
Libya (Benghazi)																		
2003-2004				8			4			2			7			7		
Tunisia (Central)																		
1996-1999				9			7			4			15	53·4 [§]	16·2 - 90·7	5		
2000-2004				2			3			1			3			3		
2005-2007				2			2			5			8			1		
AMERICA (Central and South)																		
Argentina *																		
2000-2004	68	32·0	20·7 - 43·3	768	72·9	69·6 - 76·1	560	66·6	62·5 - 70·6	389	57·8	52·8 - 62·8	952	63·5	60·2 - 66·8	833	65·6	62·1 - 69·1
2005-2009	58	37·0	23·9 - 50·0	768	76·9	73·7 - 80·0	472	69·5	65·3 - 73·8	413	57·0	52·0 - 62·0	961	66·3	63·0 - 69·7	750	67·2	63·6 - 70·8
Brazilian registries																		
1996-1999	3			29	79·5	65·1 - 94·0	21	76·2	58·5 - 94·0	11	63·7	36·9 - 90·6	32	75·5 ^R	64·8 - 86·2	32	72·1	56·7 - 87·5
2000-2004	6			76	83·2	74·7 - 91·6	51	68·7	56·1 - 81·3	35	53·2	36·7 - 69·7	90	67·8	57·7 - 78·0	78	66·5	55·9 - 77·0
2005-2009	4			67	77·5	68·1 - 87·0	40	70·6	58·2 - 83·0	21	52·1	33·9 - 70·3	66	63·2	52·4 - 74·0	66	70·8	59·4 - 82·1
Chilean registries																		
1998-1999				9			8						14	35·8	12·6 - 58·9	3		
2000-2004	1			10	60·1	31·6 - 88·5	7			3			13	77·0	55·1 - 99·0	8		
2005-2008				11	59·4	30·5 - 88·3	8			4			9			14	79·1	58·8 - 99·4
Colombia (Cali)																		
1995-1999	8			55	34·9	22·1 - 47·6	42	59·3	42·9 - 75·6	19	26·6	7·8 - 45·4	73	37·4	25·0 - 49·7	51	49·8 ^R	38·7 - 60·8
2000-2004	5			54	57·8	44·4 - 71·1	47	49·2	33·9 - 64·4	30	39·9	21·4 - 58·3	74	51·7	39·5 - 63·9	62	47·3	34·8 - 59·8
2005-2009	4			45	71·9	58·6 - 85·3	38	53·6	34·7 - 72·6	30	32·1	15·1 - 49·2	51	54·2	40·6 - 67·8	66	53·3	41·0 - 65·6

Web-table 2: Precursor-cell lymphoid leukaemia (ICCC3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Ecuador (Quito)																		
1995-1999	2			25	64·1	45·8 - 82·5	33	66·8	51·0 - 82·6	21	57·4	37·1 - 77·8	41	58·3 ^R	46·6 - 70·0	40	70·0	56·8 - 83·1
2000-2004	5			45	66·8	53·2 - 80·5	39	66·8	52·2 - 81·4	21	57·4	36·8 - 77·9	49	60·1	46·4 - 73·9	61	67·8	55·6 - 80·0
2005-2009				45	66·6	53·8 - 79·4	24	74·7	58·6 - 90·7	26	47·8	30·2 - 65·5	52	66·7	54·5 - 78·9	43	61·1 ^R	50·6 - 71·5
Puerto Rico *																		
2000-2004	1			32	81·4	68·1 - 94·7	14	85·8	68·1 - 100·0	26	69·3	51·9 - 86·6	40	68·2 ^R	56·9 - 79·5	33	90·5 ^R	81·8 - 99·2
2005-2009	5			41	80·1	66·8 - 93·4	16	81·3	62·8 - 99·8	19	72·8	54·7 - 90·9	56	74·9	61·6 - 88·2	25	<i>81·2</i>	<i>66·6 - 95·8</i>
AMERICA (North)																		
Canada *																		
1995-1999	35	54·5	38·3 - 70·8	604	91·8	89·6 - 94·0	326	88·4	84·9 - 91·9	169	79·4	73·3 - 85·5	634	84·8	81·5 - 88·0	500	87·8	84·1 - 91·4
2000-2004	31	51·8	34·5 - 69·0	545	95·3	93·5 - 97·1	320	91·6	88·6 - 94·6	178	88·3	83·6 - 93·0	626	89·8	87·0 - 92·5	448	92·6	89·7 - 95·5
2005-2009	31	48·3	31·5 - 65·2	571	94·6	92·7 - 96·5	320	93·8	91·2 - 96·5	175	86·3	80·9 - 91·6	628	90·2	87·3 - 93·0	469	91·5	88·4 - 94·7
US registries																		
1995-1999	259	55·8	49·7 - 61·9	3,907	90·8	89·9 - 91·8	2,252	86·6	85·2 - 88·1	1,252	73·3	70·8 - 75·7	4,261	81·5	80·1 - 82·9	3,409	84·6	83·1 - 86·0
2000-2004	335	60·0	54·7 - 65·3	4,519	93·0	92·3 - 93·8	2,448	89·5	88·3 - 90·8	1,540	79·6	77·5 - 81·6	4,855	86·0	84·9 - 87·2	3,987	87·4	86·2 - 88·6
2005-2009	337	59·4	54·1 - 64·7	4,983	94·4	93·7 - 95·0	2,688	90·6	89·5 - 91·7	1,727	80·5	78·5 - 82·4	5,400	86·9	85·8 - 88·0	4,335	88·7	87·6 - 89·9
ASIA																		
Chinese registries																		
1995-1999	1			11	9·1	0·0 - 22·5	11	18·2	0·0 - 38·0	5			14	<i>0·0</i>		14	<i>17·9</i>	<i>0·0 - 36·6</i>
2000-2004	2			34	49·0	32·2 - 65·8	25	71·1	53·4 - 88·8	23	29·0	10·9 - 47·1	45	54·4	40·7 - 68·2	39	42·4	30·2 - 54·6
2005-2009	8			58	84·2	74·0 - 94·4	45	76·9	63·6 - 90·2	40	52·6	34·3 - 71·0	92	73·0	63·2 - 82·8	59	63·3	49·2 - 77·4
Cyprus *																		
2004-2009	1			14	92·4 ^M	78·4 - 100·0	10	100·0 ^M	100·0 - 100·0	9			18	<i>93·4</i> ^M	<i>81·2 - 100·0</i>	16	<i>73·2</i> ^M	<i>51·2 - 95·2</i>
India (Karunagappally)																		
1995-1999	1			6			8			2			11	<i>63·9</i>	<i>37·0 - 90·9</i>	6		
2000-2004				6			3			5			9			5		
2005-2009				6			5			1			10	<i>74·8</i>	<i>50·8 - 98·9</i>	2		
Indonesia (Jakarta)																		
2005-2007				5			5			4			8			6		

Web-table 2: Precursor-cell lymphoid leukaemia (ICCC3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

	Calendar	Age group (years)												Sex					
		<1			1-4			5-9			10-14			Boys			Girls		
		N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Israel *																			
	1995-1999	7			88	93·3	88·0 - 98·5	63	82·6	73·3 - 91·9	30	66·7	50·2 - 83·2	102	78·6	69·7 - 87·5	86	83·8	75·0 - 92·6
	2000-2004	9			121	91·8	86·9 - 96·7	87	87·4	80·5 - 94·4	41	83·0	71·6 - 94·4	144	87·6	81·5 - 93·6	114	84·1	76·4 - 91·9
	2005-2009	10	42·4	16·8 - 68·0	136	93·2	88·8 - 97·5	67	86·8	79·2 - 94·4	58	78·2	67·2 - 89·2	155	82·5	75·8 - 89·1	116	87·5	80·9 - 94·0
Japanese registries																			
	1995-1999	11	45·6	18·1 - 73·1	140	82·8	76·5 - 89·0	82	87·9	80·8 - 94·9	61	66·2	54·3 - 78·2	167	75·7	68·9 - 82·6	127	81·2	73·8 - 88·6
	2000-2004	15	64·4	40·4 - 88·4	202	89·8	85·4 - 94·2	118	79·1	71·5 - 86·7	71	66·7	55·1 - 78·3	229	71·6	64·6 - 78·6	177	85·8	79·6 - 91·9
	2005-2009	12	73·8	49·5 - 98·1	109	92·4	88·1 - 96·7	84	83·8	76·9 - 90·6	54	71·6	60·5 - 82·6	140	77·3	70·7 - 84·0	119	87·8	82·0 - 93·7
Korea * ‡																			
	1995-1999	49	34·9	21·7 - 48·0	528	74·4	70·6 - 78·1	353	67·5	62·6 - 72·4	241	51·1	44·8 - 57·4	674	60·7	56·7 - 64·6	497	66·4	62·1 - 70·7
	2000-2004	48	41·8	28·1 - 55·5	514	84·1	81·0 - 87·3	383	76·6	72·3 - 80·8	252	62·4	56·4 - 68·3	724	72·8	69·3 - 76·3	473	73·8	69·6 - 78·0
	2005-2009	53	46·6	33·0 - 60·2	460	84·6	81·4 - 87·9	326	79·7	75·4 - 84·0	298	70·6	65·2 - 75·9	630	77·4	74·0 - 80·7	507	76·8	72·9 - 80·7
Malaysia (Penang)																			
	1995-1999	3			22	82·0	66·2 - 97·7	16	87·6	71·9 - 100·0	10	60·1	31·6 - 88·6	32	78·3	64·2 - 92·4	19	84·2	68·3 - 100·0
	2000-2004	6			25	92·1	81·7 - 100·0	16	87·5	71·9 - 100·0	4			26	92·5	82·4 - 100·0	25	80·0	64·7 - 95·4
	2005-2009				25	84·2	68·1 - 100·0	17	81·2	62·5 - 99·9	15	42·6	16·0 - 69·3	36	82·5 ^R	71·4 - 93·6	21	61·1	40·6 - 81·7
Mongolia *																			
	2005-2009	3			4			11	0·0	0·0 - 0·0	6			17	0·0	0·0 - 0·0	7		
Taiwan *																			
	1995-1999	23	30·6	12·5 - 48·6	282	74·6	69·5 - 79·6	172	66·9	59·9 - 73·9	124	49·3	40·5 - 58·0	346	63·5	58·3 - 68·7	255	60·9	54·2 - 67·5
	2000-2004	36	33·5	18·4 - 48·5	317	82·7	78·6 - 86·9	196	77·1	71·2 - 83·0	116	61·3	52·5 - 70·1	381	69·1	64·0 - 74·2	284	76·1	70·4 - 81·7
	2005-2009	26	31·5	15·2 - 47·8	277	86·5	82·7 - 90·4	168	81·5	75·7 - 87·3	139	71·2	63·3 - 79·1	355	77·2	72·6 - 81·9	255	79·4	74·0 - 84·8
Thai registries																			
	1995-1999	8			55	48·3	34·4 - 62·1	25	50·0	30·2 - 69·7	14	54·7	29·0 - 80·3	52	44·9 ^R	33·1 - 56·6	50	57·4 ^R	45·1 - 69·7
	2000-2004	7			53	69·5	57·0 - 82·0	42	63·8	49·3 - 78·4	18	44·6	22·6 - 66·6	74	57·1	45·5 - 68·6	46	66·5 ^R	55·2 - 77·7
	2005-2009	4			36	62·5	47·7 - 77·3	32	47·1	30·9 - 63·4	30	53·8	34·2 - 73·3	58	52·3	40·1 - 64·6	44	58·4	42·8 - 74·1

Web-table 2: Precursor-cell lymphoid leukaemia (ICCC3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Turkey (Izmir)																		
1995-1999	5			56	65·3	52·4 - 78·3	31	69·5	52·2 - 86·8	24	57·8	37·3 - 78·2	60	57·4^R	46·6 - 68·2	56	71·6	58·8 - 84·5
2000-2004	3			62	73·9	62·9 - 84·9	41	82·5	70·8 - 94·2	25	56·6	36·9 - 76·3	68	64·2	51·8 - 76·6	63	76·2	64·8 - 87·7
2005-2009	6			78	80·6	71·6 - 89·6	49	84·2	73·5 - 95·0	28	62·0	44·7 - 79·3	83	74·2	63·1 - 85·2	78	72·4	62·0 - 82·7
EUROPE																		
Austria *																		
1995-1999	5			126	95·3	91·6 - 99·0	74	86·5	78·8 - 94·3	35	80·1	67·0 - 93·1	142	88·3	81·8 - 94·8	98	84·1	75·6 - 92·6
2000-2004	6			98	97·0	93·6 - 100·0	57	87·8	79·3 - 96·2	47	85·2	75·1 - 95·3	110	92·9	87·7 - 98·0	98	86·4	79·2 - 93·5
2005-2009	9			100	99·1	97·1 - 100·0	72	89·8	82·7 - 97·0	40	86·3	76·1 - 96·4	123	94·6	90·1 - 99·1	98	87·1	79·2 - 95·0
Belarus *																		
1995-1999	8			112	83·2	76·2 - 90·1	96	80·1	72·1 - 88·1	66	63·8	52·3 - 75·3	156	70·2	63·0 - 77·3	126	81·2	74·0 - 88·4
2000-2004	2			110	84·6	77·9 - 91·4	62	82·1	72·6 - 91·7	61	69·0	57·5 - 80·5	133	78·3	71·0 - 85·6	102	78·6	70·5 - 86·7
2005-2009	8			101	91·1	85·4 - 96·7	65	92·0	85·3 - 98·8	35	84·2	73·5 - 95·0	101	91·2	85·5 - 96·9	108	86·1	79·1 - 93·1
Belgium *																		
2004-2009	12	33·1^M	6·5 - 59·7	191	93·2^M	88·6 - 97·9	105	86·1^M	78·4 - 93·9	78	84·8^M	75·5 - 94·1	230	87·1^M	81·5 - 92·6	156	87·7^M	81·4 - 94·0
Bulgaria *																		
1995-1999	10	20·2	0·0 - 41·4	68	63·4	52·0 - 74·8	47	66·0	52·7 - 79·4	41	48·9	33·8 - 63·9	86	52·0	42·0 - 62·0	80	63·2	52·8 - 73·6
2000-2004	4			67	76·3	66·1 - 86·4	53	58·6	45·5 - 71·7	30	53·5	36·0 - 70·9	86	61·1	50·5 - 71·8	68	62·2	50·6 - 73·8
2005-2009	6			95	82·3	74·1 - 90·6	76	74·1	63·3 - 85·0	38	61·8	46·5 - 77·0	119	67·4	57·9 - 76·9	96	76·3	66·4 - 86·3
Croatia *																		
1998-1999	2			20	90·1	77·3 - 100·0	14	78·6	58·0 - 99·3	8			17	<i>64·8</i>	<i>42·9 - 86·8</i>	27	<i>77·9</i>	<i>62·6 - 93·2</i>
2000-2004	5			87	91·0	84·9 - 97·0	47	85·2	75·1 - 95·2	21	71·4	52·7 - 90·2	95	76·9	67·0 - 86·8	65	90·2^R	84·2 - 96·3
2005-2009	2			61	93·8	87·7 - 99·8	41	82·5	70·8 - 94·2	42	82·3	70·4 - 94·1	89	85·0	77·2 - 92·8	57	88·0	79·9 - 96·2
Denmark *																		
1995-1999	1			96	87·5	81·0 - 94·1	38	86·9	76·3 - 97·5	28	82·2	68·3 - 96·1	89	84·8	76·7 - 92·9	74	87·3	78·5 - 96·0
2000-2004	5			114	92·2	87·2 - 97·1	49	83·7	73·5 - 94·0	41	78·1	65·7 - 90·6	125	83·2	75·6 - 90·7	84	86·3	78·2 - 94·5
2005-2009	4			92	93·0	88·0 - 98·0	55	84·8	75·2 - 94·5	20	85·4	72·4 - 98·4	97	85·7	77·9 - 93·6	74	89·2	81·5 - 96·9

Web-table 2: Precursor-cell lymphoid leukaemia (ICCC3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

	Calendar	Age group (years)												Sex					
		<1			1-4			5-9			10-14			Boys			Girls		
		N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Estonia *																			
	1995-1999	1			11	72·8	47·8 - 97·7	10	30·0	4·5 - 55·6	7			9			20	50·1	28·9 - 71·2
	2000-2004				13	75·6	52·6 - 98·7	7			11	45·6	18·1 - 73·0	17	56·6	33·3 - 79·9	14	64·4	40·4 - 88·4
	2005-2008	1			5			1			6			6			7		
Finland *																			
	1995-1999	6			102	89·3	83·3 - 95·3	51	76·5	65·0 - 88·0	34	82·4	69·8 - 95·0	100	86·9	79·7 - 94·2	93	78·0	68·4 - 87·7
	2000-2004	6			117	90·6	85·4 - 95·9	44	88·7	79·4 - 98·0	24	75·1	58·2 - 92·0	102	81·1	72·1 - 90·1	89	90·9 ^R	85·4 - 96·5
	2005-2009	14	69·3	41·5 - 97·2	99	87·3	80·9 - 93·8	59	81·5	71·1 - 91·9	33	78·0	62·4 - 93·7	118	79·2	70·0 - 88·5	87	84·0	74·7 - 93·4
France *																			
	1995-1999	49	47·1	33·3 - 60·9	833	88·8	86·6 - 90·9	522	86·8	83·9 - 89·7	324	74·0	69·2 - 78·8	960	81·9	79·2 - 84·6	768	83·2	80·2 - 86·2
	2000-2004	51	60·9	47·6 - 74·2	873	93·3	91·6 - 95·0	530	89·1	86·4 - 91·7	339	83·8	79·9 - 87·8	957	86·4	84·0 - 88·8	836	90·4	88·1 - 92·7
	2005-2009	53	43·9	30·0 - 57·9	888	94·7	93·2 - 96·2	535	91·4	89·0 - 93·8	352	84·1	80·1 - 88·0	1,015	87·2	84·9 - 89·6	813	91·9	89·7 - 94·0
German registries																			
	1995-1999	11	70·2	43·4 - 97·1	204	91·7	87·9 - 95·5	153	87·6	82·4 - 92·8	100	81·1	73·4 - 88·8	274	85·0	80·5 - 89·6	194	88·5	83·6 - 93·4
	2000-2004	17	63·5	40·9 - 86·1	281	89·4	85·8 - 93·0	186	89·8	85·4 - 94·2	158	83·6	77·8 - 89·4	363	87·0	83·4 - 90·5	279	86·9	82·6 - 91·1
	2005-2009	31	55·4	36·8 - 74·0	501	94·0	91·6 - 96·4	280	93·1	89·8 - 96·4	177	89·7	85·1 - 94·2	535	90·3	87·4 - 93·3	454	93·2	90·4 - 96·0
Iceland *																			
	1995-1999	1			6			2						6			3		
	2000-2004	3			4			1			1			5			4		
	2005-2009				6			2			2			4			6		
Ireland *																			
	1995-1999	4			78	84·7	76·7 - 92·6	39	87·2	76·9 - 97·6	25	68·1	50·2 - 86·0	78	82·7	73·7 - 91·7	68	76·0	65·1 - 86·9
	2000-2004	4			63	88·9	81·2 - 96·6	43	86·1	75·9 - 96·3	35	77·2	63·5 - 90·9	79	86·1	78·3 - 94·0	66	79·2	69·3 - 89·0
	2005-2009	10	56·1	25·4 - 86·8	91	97·1	93·1 - 100·0	34	87·6	77·6 - 97·7	27	73·9	58·6 - 89·2	93	88·9	81·6 - 96·2	69	79·1	68·5 - 89·8
Italian registries																			
	1995-1999	21	43·0	22·6 - 63·4	302	89·8	86·4 - 93·2	214	85·8	81·1 - 90·6	124	78·5	71·2 - 85·8	358	83·1	78·7 - 87·4	303	84·6	80·1 - 89·0
	2000-2004	33	69·4	53·8 - 85·0	375	94·4	92·1 - 96·8	203	87·7	83·2 - 92·2	114	67·3	58·7 - 75·9	411	80·8	76·5 - 85·2	314	85·2	80·1 - 90·2
	2005-2009	13	51·9	30·3 - 73·6	257	94·2	91·7 - 96·7	148	85·1	80·0 - 90·2	89	87·0	80·3 - 93·6	269	84·4	79·8 - 89·0	238	92·1	88·7 - 95·4

Web-table 2: Precursor-cell lymphoid leukaemia (ICCC3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

	Calendar	Age group (years)												Sex					
		<1			1-4			5-9			10-14			Boys			Girls		
		N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Latvia *																			
	1995-1999	2			5			3			5			6			9		
	2000-2004				21	95·4	86·5 - 100·0	8			6			18	89·1	75·0 - 100·0	17	94·1	83·3 - 100·0
	2005-2009				24	87·1	73·6 - 100·0	14	71·9	45·9 - 97·8	7			24	71·5 ^R	56·6 - 86·5	21	89·3	75·5 - 100·0
Lithuania *																			
	1995-1999	1			54	57·5	44·5 - 70·5	29	69·0	52·5 - 85·5	18	50·2	27·9 - 72·4	65	61·1	49·1 - 73·0	37	58·2 ^R	45·2 - 71·3
	2000-2004	3			44	81·9	70·6 - 93·2	41	75·3	62·1 - 88·5	18	66·7	45·7 - 87·8	53	81·8 ^R	73·5 - 90·0	53	69·1 ^R	59·4 - 78·9
	2005-2009	2			46	91·1	82·8 - 99·4	27	74·4	58·3 - 90·5	11	44·2	18·6 - 69·7	36	79·4	65·9 - 92·9	50	70·6 ^R	60·7 - 80·6
Malta *																			
	1995-1999				9			7			3			12	66·7	41·4 - 92·1	7		
	2000-2004				5			8			3			11	81·9	60·2 - 100·0	5		
	2005-2009				10	90·2	72·5 - 100·0	3			4			8			9		
Netherlands *																			
	1995-1999	17	35·4	13·8 - 56·9	281	88·0	84·1 - 91·8	143	82·3	76·0 - 88·6	86	75·7	66·6 - 84·7	335	81·2	76·4 - 86·0	192	80·2	73·5 - 86·9
	2000-2004	24	62·7	43·7 - 81·6	290	92·4	89·4 - 95·5	159	89·4	84·6 - 94·1	109	72·5	64·2 - 80·9	347	83·2	78·9 - 87·5	235	85·1	79·7 - 90·5
	2005-2009	23	67·0	47·4 - 86·6	245	89·4	85·7 - 93·1	180	89·9	85·3 - 94·4	85	81·1	73·0 - 89·1	291	86·1	81·7 - 90·4	242	86·6	81·4 - 91·8
Norway *																			
	1995-1999	6			96	88·4	82·0 - 94·9	54	79·7	69·0 - 90·3	21	70·5	51·1 - 89·8	88	77·3	66·9 - 87·6	89	81·0	70·1 - 91·9
	2000-2004	4			97	86·3	79·4 - 93·2	47	89·4	80·7 - 98·1	30	86·7	74·8 - 98·7	94	86·5	78·6 - 94·3	84	89·1	82·3 - 96·0
	2005-2009	9			94	92·0	86·3 - 97·7	41	93·5	86·4 - 100·0	25	85·9	73·3 - 98·6	84	91·4	85·1 - 97·7	85	88·2	80·2 - 96·2
Poland (Wroclaw)																			
	2000-2004	2			15	80·1	60·5 - 99·6	6			10	50·0	21·2 - 78·8	18	61·2	39·4 - 82·9	15	80·0	60·5 - 99·5
	2005-2009	2			25	89·8	76·4 - 100·0	18	86·2	69·0 - 100·0	17	65·9	44·5 - 87·3	44	78·0	65·2 - 90·8	18	88·3	73·3 - 100·0
Portugal *																			
	1998-1999	4			22	76·3	58·5 - 94·0	12	63·7	36·8 - 90·5	7			20	68·5	48·2 - 88·8	25	62·7	43·8 - 81·5
	2000-2004	10	90·5	72·8 - 100·0	110	89·0	83·1 - 94·9	71	84·5	76·1 - 92·9	47	63·9	50·4 - 77·5	131	77·8	70·1 - 85·4	107	80·7	72·5 - 89·0
	2005-2009	5			87	91·0	85·4 - 96·7	66	94·8	89·7 - 99·8	33	68·4	53·8 - 82·9	117	81·4	73·9 - 88·9	74	86·0	77·8 - 94·1

Web-table 2: Precursor-cell lymphoid leukaemia (ICCC3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Russia [†] (Arkhangelsk)																		
2000-2004	1			12	66·7	41·4 - 92·1	3			7			14	42·9	18·5 - 67·4	9		
2005-2009				11	80·1	56·6 - 100·0	7			5			14	77·1	55·1 - 99·1	9		
Slovakia *																		
2000-2004	4			59	88·2	80·0 - 96·4	39	84·7	73·5 - 95·8	29	69·1	52·6 - 85·6	69	85·5	77·0 - 94·1	62	71·8	60·1 - 83·6
2005-2007	3			44	92·2	83·8 - 100·0	24	83·9	69·6 - 98·2	18	60·6	40·1 - 81·2	56	78·3	66·9 - 89·8	33	82·4	69·8 - 95·1
Slovenia *																		
1995-1999	3			25	92·1	81·6 - 100·0	9			13	77·0	55·0 - 98·9	25	76·1	59·7 - 92·5	25	92·0	81·6 - 100·0
2000-2004	1			32	96·9	91·0 - 100·0	12	91·7	76·7 - 100·0	4			22	95·5	87·0 - 100·0	27	88·9	77·3 - 100·0
2005-2009	3			24	91·7	80·9 - 100·0	8			8			22	81·9	66·1 - 97·6	21	81·8	66·0 - 97·6
Spanish registries																		
1995-1999	11	27·4	3·5 - 51·2	142	85·1	79·2 - 91·0	86	82·6	74·6 - 90·6	51	58·9	45·5 - 72·2	168	74·7	67·5 - 82·0	122	73·4	65·0 - 81·7
2000-2004	12	58·5	32·0 - 84·9	149	83·2	77·2 - 89·2	79	84·9	77·0 - 92·7	68	79·4	69·8 - 89·0	174	84·4	78·8 - 90·0	134	78·3	70·6 - 85·9
2005-2009	14	85·4	67·0 - 100·0	163	90·8	86·4 - 95·3	125	88·4	82·7 - 94·1	60	73·7	63·3 - 84·0	219	85·3	80·1 - 90·5	143	82·6	75·6 - 89·6
Sweden *																		
1995-1999	12	50·1	23·4 - 76·7	184	92·9	89·2 - 96·6	95	85·3	78·2 - 92·4	53	79·3	68·5 - 90·1	197	83·9	78·1 - 89·7	147	87·1	80·3 - 93·9
2000-2004	10	50·1	21·3 - 78·9	143	95·1	91·6 - 98·7	98	85·7	78·8 - 92·6	62	82·3	72·9 - 91·8	175	88·1	83·1 - 93·1	138	84·4	77·3 - 91·6
2005-2009	7			118	90·0	84·8 - 95·2	61	85·3	77·3 - 93·3	44	83·6	73·9 - 93·4	122	86·0	80·1 - 91·9	108	85·1	77·9 - 92·4
Switzerland *																		
1995-1999	2			116	93·2	88·5 - 97·8	59	89·8	82·0 - 97·5	43	74·5	61·6 - 87·4	135	81·7	74·7 - 88·8	85	92·8	86·7 - 98·8
2000-2004	8			104	91·4	86·0 - 96·8	72	88·9	81·7 - 96·1	38	84·3	72·8 - 95·7	122	85·8	78·8 - 92·8	100	88·9	82·3 - 95·4
2005-2009	9			113	89·8	84·1 - 95·5	52	91·0	83·5 - 98·5	51	86·7	76·8 - 96·6	127	89·5	83·7 - 95·3	98	86·3	78·8 - 93·9
United Kingdom *																		
1995-1999	62	37·8	25·8 - 49·9	968	87·9	85·9 - 90·0	531	84·5	81·4 - 87·6	310	68·0	62·8 - 73·2	1,038	78·3	75·5 - 81·2	833	80·3	77·0 - 83·5
2000-2004	76	63·1	52·3 - 74·0	953	92·1	90·3 - 93·8	569	89·0	86·4 - 91·5	356	79·2	75·0 - 83·5	1,115	85·1	82·7 - 87·5	839	87·4	84·8 - 89·9
2005-2009	63	57·8	46·5 - 69·1	1,001	93·5	91·9 - 95·0	490	91·5	89·2 - 93·9	339	85·1	81·3 - 88·9	1,036	87·7	85·4 - 90·0	857	91·2	89·0 - 93·4

Web-table 2: Precursor-cell lymphoid leukaemia (ICCC3 Ia1) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
OCEANIA																		
Australian registries																		
1995-1999	17	41·3	19·0 - 63·6	340	88·6	85·2 - 92·0	204	85·3	80·5 - 90·2	121	76·9	69·5 - 84·4	363	80·3	75·7 - 84·9	319	85·9	81·6 - 90·2
2000-2004	28	60·7	42·9 - 78·5	425	92·0	89·4 - 94·7	235	84·6	80·0 - 89·2	137	83·8	77·6 - 90·0	445	82·5	78·4 - 86·6	380	90·5	87·1 - 94·0
2005-2009	12	62·7	39·9 - 85·5	327	95·0	92·7 - 97·3	156	92·1	88·3 - 96·0	122	81·3	74·3 - 88·4	352	90·3	86·8 - 93·7	265	86·6	81·8 - 91·3
New Zealand *																		
1995-1999	4			89	90·0	83·7 - 96·2	45	80·1	68·5 - 91·6	29	79·4	64·9 - 93·9	104	85·1	77·4 - 92·8	63	78·4	67·1 - 89·6
2000-2004	5			93	94·7	90·1 - 99·2	52	90·4	82·5 - 98·4	32	75·1	60·4 - 89·9	103	92·0	85·7 - 98·3	79	78·8	69·2 - 88·4
2005-2009	6			77	94·8	89·8 - 99·8	62	87·1	78·1 - 96·0	31	87·9	75·3 - 100·0	93	92·5	86·3 - 98·7	83	86·1	77·5 - 94·7

Web-table 3

Acute myeloid leukaemia (ICCC-3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Net survival estimates by sex were age-standardised where possible. Estimates in italics are not age-standardised

* National coverage – the data are derived from a population-based cancer registry (registries) covering the entire country

^M Estimate based on merging data for 2 (or all 3) calendar periods

^R Age-standardised estimate computed by pooling two age-specific estimates and re-estimation

[§] Estimate judged as less reliable

‡ Korea: Republic of Korea; Russia: Russian Federation

Web-table 3: Acute myeloid leukaemia (ICCC3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
AFRICA																		
Algerian registries																		
2000-2004	2			3			5			3			11	16·0 [§]	0·0 - 38·0	2		
2005-2009	1			4			1			1			3			4		
Libya (Benghazi)																		
2003-2004				5									1			4		
Tunisia (Central)																		
1996-1999				2			1						2			1		
2000-2004	1						1						2					
2005-2007				2						1			2			1		
AMERICA (Central and South)																		
Brazilian registries																		
1996-1999	1			5			4			3			7			6		
2000-2004	5			11	27·4	3·7 - 51·1	15	66·7	43·8 - 89·6	10	40·1	12·2 - 68·0	28	45·4 ^R	33·0 - 57·8	13	54·1	28·3 - 79·9
2005-2009	3			5			8			9			17	47·0	27·3 - 66·7	8		
Chilean registries																		
1998-1999				2						1			2			1		
2000-2004										2			2					
2005-2008	1			4			3			1			8			1		
Ecuador (Quito)																		
1995-1999	3			5			12	41·7	15·7 - 67·7	13	46·3	20·7 - 71·9	16	62·9	40·0 - 85·8	17	35·5	14·1 - 57·0
2000-2004	2			5			4			7			10	50·3	21·4 - 79·1	8		
2005-2009	3			7			1			5			8			8		
Puerto Rico *																		
2000-2004	1			4			6			6			10	60·1	31·6 - 88·5	7		
2005-2009	2			5			4			7			8			10	44·4	16·9 - 71·8

Web-table 3: Acute myeloid leukaemia (ICCC3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
AMERICA (North)																		
Canada *																		
1995-1999	31	61·6	44·8 - 78·5	80	56·3	45·5 - 67·1	51	56·9	43·5 - 70·3	73	53·5	42·2 - 64·8	118	53·9	44·7 - 63·1	117	58·0	48·8 - 67·2
2000-2004	28	57·4	39·6 - 75·2	58	69·0	57·3 - 80·8	48	56·3	42·5 - 70·1	54	70·4	58·4 - 82·5	85	65·9	55·9 - 75·9	103	63·5	53·9 - 73·0
2005-2009	26	69·2	51·4 - 86·9	67	78·8	68·6 - 89·1	42	68·9	55·4 - 82·3	65	70·3	58·4 - 82·1	110	70·5	61·2 - 79·8	90	74·3	65·2 - 83·4
US registries																		
1995-1999	193	45·4	38·3 - 52·5	547	54·4	50·2 - 58·6	336	55·7	50·4 - 61·0	498	46·9	42·5 - 51·3	854	52·1	48·6 - 55·7	720	50·7	46·9 - 54·5
2000-2004	262	57·6	51·6 - 63·6	602	62·6	58·8 - 66·5	369	60·4	55·4 - 65·4	566	57·7	53·6 - 61·8	976	59·9	56·6 - 63·2	823	59·6	56·1 - 63·1
2005-2009	295	60·6	55·0 - 66·2	650	66·2	62·5 - 69·9	354	63·5	58·5 - 68·5	599	61·8	57·9 - 65·7	976	63·3	60·1 - 66·6	922	63·1	59·7 - 66·5
ASIA																		
Chinese registries																		
1995-1999				6			10	10·0	0·0 - 24·5	11	0·0		18	<i>5·6</i>	<i>0·0 - 13·9</i>	9		
2000-2004	2			8			18	27·5	6·4 - 48·6	33	15·2	3·6 - 26·7	39	15·9^R	6·9 - 24·8	22	<i>26·0</i>	<i>8·3 - 43·8</i>
2005-2009	3			13	33·0	6·5 - 59·6	20	46·0	22·5 - 69·5	25	39·5	19·7 - 59·2	36	38·8	22·5 - 55·1	25	<i>44·0</i>	<i>24·2 - 63·8</i>
Cyprus *																		
2004-2009	1			2			2			5			6			4		
India (Karunagappally)																		
1995-1999										1			1					
2000-2004							2			2			1			3		
2005-2009				1			1			1			3					
Indonesia (Jakarta)																		
2005-2007							3			3			3			3		
Israel *																		
1995-1999	2			13	53·9	28·2 - 79·6	9			16	56·3	33·0 - 79·6	26	61·7^R	47·4 - 76·1	14	<i>64·3</i>	<i>40·3 - 88·3</i>
2000-2004	8			20	70·1	50·8 - 89·4	14	78·6	57·9 - 99·2	25	56·0	37·1 - 75·0	30	70·4^R	57·7 - 83·1	37	63·5	49·5 - 77·6
2005-2009	11	54·7	27·0 - 82·4	28	65·3	47·2 - 83·3	16	83·6	67·1 - 100·0	23	53·2	33·5 - 72·8	41	64·0^R	51·6 - 76·3	37	66·0^R	54·5 - 77·5

Web-table 3: Acute myeloid leukaemia (ICCC3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Japanese registries																		
1995-1999	19	62.9	41.7 - 84.2	27	55.6	37.3 - 73.9	28	67.9	51.0 - 84.8	48	60.5	46.8 - 74.1	71	61.4	50.4 - 72.4	51	62.3 ^R	51.9 - 72.7
2000-2004	24	72.9	54.7 - 91.1	69	69.0	57.8 - 80.2	48	56.9	42.6 - 71.3	40	56.7	41.4 - 71.9	96	63.3	53.1 - 73.6	85	59.1	47.8 - 70.5
2005-2009	13	70.8	50.0 - 91.7	37	76.2	64.8 - 87.5	31	62.9	49.1 - 76.6	30	70.3	55.8 - 84.8	57	73.7	64.2 - 83.3	54	65.7	54.8 - 76.7
Korea * [‡]																		
1995-1999	44	22.8	10.8 - 34.9	151	45.8	37.8 - 53.7	120	44.2	35.4 - 53.0	167	35.4	28.2 - 42.6	283	39.9	34.1 - 45.6	199	40.3	33.4 - 47.1
2000-2004	37	51.5	35.7 - 67.4	146	48.0	39.9 - 56.1	149	51.0	43.1 - 59.0	172	49.5	42.0 - 56.9	283	46.4	40.6 - 52.1	221	53.8	47.2 - 60.4
2005-2009	49	47.4	33.6 - 61.2	95	55.5	46.0 - 65.1	117	53.7	45.0 - 62.5	172	55.5	48.2 - 62.8	243	53.4	47.3 - 59.6	190	54.4	47.4 - 61.3
Malaysia (Penang)																		
1995-1999	1			10	60.0	31.6 - 88.5	4			7			13	<i>53.9</i>	<i>28.2 - 79.6</i>	9		
2000-2004	2			9			8			4			14	<i>71.5</i>	<i>48.8 - 94.2</i>	9		
2005-2009	3			7			8			4			8			14	<i>33.5</i>	<i>10.3 - 56.7</i>
Mongolia *																		
2005-2009				3			2			3			3			5		
Taiwan *																		
1995-1999	31	32.4	16.4 - 48.4	53	41.6	28.5 - 54.6	46	45.7	31.5 - 59.8	65	38.5	26.8 - 50.2	102	40.0	30.2 - 49.7	93	42.1	32.1 - 52.1
2000-2004	21	38.3	18.3 - 58.3	71	49.3	37.8 - 60.9	49	51.0	37.3 - 64.8	73	48.0	36.7 - 59.4	122	47.9	39.0 - 56.9	92	49.7	39.6 - 59.8
2005-2009	23	52.8	33.8 - 71.9	56	60.3	47.6 - 73.1	59	60.3	47.8 - 72.8	67	48.7	37.0 - 60.4	116	56.3	47.4 - 65.1	89	54.2	43.9 - 64.4
Thai registries																		
1995-1999	3			5			5			5			9			9		
2000-2004	1			8			11	36.5	10.3 - 62.7	11	31.2	5.2 - 57.3	18	<i>36.0</i>	<i>14.3 - 57.7</i>	13	<i>23.1</i>	<i>2.4 - 43.9</i>
2005-2009	7			12	17.9	0.0 - 37.5	6			11	57.1	30.0 - 84.2	18	<i>35.5</i>	<i>15.1 - 55.9</i>	18	<i>53.1</i>	<i>28.2 - 78.0</i>
Turkey (Izmir)																		
1995-1999	7			7			13	61.6	36.4 - 86.7	7			16	<i>43.8</i>	<i>20.7 - 67.0</i>	18	<i>75.2</i>	<i>54.7 - 95.8</i>
2000-2004	2			8			8			6			14	<i>39.8</i>	<i>14.8 - 64.8</i>	10	<i>20.1</i>	<i>0.0 - 41.6</i>
2005-2009	4			6			4			14	35.8	12.3 - 59.3	15	<i>47.1</i>	<i>21.2 - 73.0</i>	13	<i>40.0</i>	<i>13.2 - 66.7</i>

Web-table 3: Acute myeloid leukaemia (ICCC3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

	Calendar	Age group (years)												Sex					
		<1			1-4			5-9			10-14			Boys			Girls		
		N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
EUROPE																			
Austria *																			
	1995-1999	1			21	61·9	41·8 - 82·1	4			21	57·2	36·8 - 77·6	29	58·7 ^R	44·9 - 72·5	18	61·1	39·5 - 82·7
	2000-2004	6			10	60·0	31·6 - 88·4	9			15	66·7	43·8 - 89·6	21	66·8	47·2 - 86·4	19	63·2	42·2 - 84·2
	2005-2009	2			12	77·8	52·3 - 100·0	9			12	66·4	43·4 - 89·4	16	87·6	71·9 - 100·0	19	59·7	38·8 - 80·5
Belgium *																			
	2004-2009	10	53·5 ^M	22·0 - 85·0	24	42·2 ^M	20·6 - 63·9	17	63·7 ^M	39·2 - 88·3	17	60·2 ^M	35·9 - 84·5	31	48·5 ^M	29·4 - 67·7	37	58·5 ^M	44·5 - 72·6
Bulgaria *																			
	1995-1999	1			9			8			10	50·1	21·3 - 78·9	17	23·6	4·9 - 42·3	11	36·4	10·2 - 62·6
	2000-2004	4			10	30·1	4·5 - 55·7	7			14	21·5	2·0 - 41·0	23	30·5	12·5 - 48·5	12	8·4	0·0 - 20·7
	2005-2009	3			8			10	33·8	6·0 - 61·6	12	46·5	18·3 - 74·7	16	34·1	14·6 - 53·6	17	24·7	2·4 - 46·9
Croatia *																			
	1998-1999	1			7			2			3			8			5		
	2000-2004	2			7			7			4			13	61·6	36·4 - 86·7	7		
	2005-2009	2			12	64·4	37·8 - 91·0	7			7			15	53·2	28·5 - 78·0	13	58·4	32·0 - 84·7
Denmark *																			
	1995-1999	4			11	72·8	48·8 - 96·7	8			9			13	53·9	28·7 - 79·0	19	63·2	42·2 - 84·2
	2000-2004	7			22	68·2	49·3 - 87·1	5			8			19	63·2	42·2 - 84·2	23	74·0	56·6 - 91·3
	2005-2009	6			18	83·8	67·4 - 100·0	9			5			17	63·2	40·7 - 85·7	21	73·0	55·3 - 90·7
Estonia *																			
	1995-1999				1			2			4			6			1		
	2000-2004	2						1			8			6			5		
	2005-2008	3			2						1			3			3		
Finland *																			
	1995-1999	4			15	86·7	70·1 - 100·0	9			9			19	68·5	48·2 - 88·7	18	88·9	74·8 - 100·0
	2000-2004	4			10	70·0	43·3 - 96·8	3			12	66·7	41·4 - 92·1	15	53·4	29·3 - 77·5	14	78·6	58·0 - 99·3
	2005-2009	3			15	75·5	55·3 - 95·6	9			8			16	73·7	52·4 - 95·1	19	66·5	46·9 - 86·1

Web-table 3: Acute myeloid leukaemia (ICCC3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

	Calendar	Age group (years)												Sex					
		<1			1-4			5-9			10-14			Boys			Girls		
		N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
France *																			
	1995-1999	61	55·9	43·6 - 68·3	120	67·6	59·2 - 75·9	89	66·0	56·2 - 75·9	110	51·0	41·7 - 60·3	187	58·2	51·0 - 65·3	193	62·5	55·4 - 69·7
	2000-2004	56	47·7	34·7 - 60·7	127	52·0	43·4 - 60·6	87	79·3	70·9 - 87·8	122	57·2	48·4 - 66·0	201	65·4	59·1 - 71·7	191	59·1	52·1 - 66·1
	2005-2009	51	72·8	60·6 - 85·0	109	57·1	48·1 - 66·1	75	83·2	74·9 - 91·5	102	63·1	53·6 - 72·6	175	68·6	61·8 - 75·3	162	70·5	63·6 - 77·5
German registries																			
	1995-1999	15	59·5	35·3 - 83·7	25	68·1	50·2 - 85·9	27	66·7	49·4 - 84·0	40	52·5	37·4 - 67·7	49	54·7	42·0 - 67·4	58	69·9	58·5 - 81·2
	2000-2004	19	63·4	42·3 - 84·4	37	78·4	65·4 - 91·5	27	74·1	57·9 - 90·3	56	65·6	53·2 - 78·0	77	70·6	60·6 - 80·6	62	70·4	58·5 - 82·4
	2005-2009	31	59·6	41·4 - 77·9	62	85·3	75·8 - 94·8	38	84·0	72·4 - 95·6	59	73·7	62·8 - 84·7	107	76·0	67·7 - 84·4	83	80·8	71·8 - 89·7
Iceland *																			
	2000-2004				1			1									2		
	2005-2009				1						3			2			2		
Ireland *																			
	1995-1999	2			11	63·7	36·8 - 90·5	7			9			14	71·5	48·8 - 94·2	15	60·0	36·3 - 83·8
	2000-2004	5			14	78·6	58·0 - 99·3	9			7			15	60·0	36·3 - 83·8	20	60·1	39·3 - 80·8
	2005-2009	7			13	64·4	40·4 - 88·3	7			8			19	69·2	49·3 - 89·2	16	62·7	41·6 - 83·8
Italian registries																			
	1995-1999	17	51·1	28·4 - 73·8	30	61·6	44·1 - 79·1	25	68·0	50·2 - 85·8	37	56·8	41·1 - 72·5	52	58·4	45·2 - 71·5	57	64·7	52·6 - 76·7
	2000-2004	7			39	66·4	51·8 - 81·1	32	74·3	59·2 - 89·4	46	67·5	54·1 - 80·8	72	66·7	56·2 - 77·2	52	67·2	54·8 - 79·6
	2005-2009	13	50·6	23·5 - 77·7	25	76·0	60·8 - 91·2	26	69·2	52·7 - 85·6	39	69·9	56·4 - 83·3	65	76·6	66·7 - 86·6	38	58·3 ^R	47·4 - 69·2
Latvia *																			
	1995-1999	1			4			6			4			7			8		
	2000-2004				2			3			6			7			4		
	2005-2009	2			2			5						6			3		
Lithuania *																			
	1995-1999	3			1			3			5			7			5		
	2000-2004	1			11	9·1	0·0 - 22·4	8			7			15	26·7	6·0 - 47·5	12	16·7	0·0 - 35·0
	2005-2009	2			4			2			6			7			7		

Web-table 3: Acute myeloid leukaemia (ICCC3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

	Calendar	Age group (years)												Sex					
		<1			1-4			5-9			10-14			Boys			Girls		
		N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Malta *																			
	2000-2004				1			3					3			1			
	2005-2009	1						1			2		2			2			
Netherlands *																			
	1995-1999	9			39	71·8	57·9 - 85·8	18	55·6	33·5 - 77·7	26	57·7	39·3 - 76·2	48	57·9	43·7 - 72·2	44	59·1 ^R	47·5 - 70·6
	2000-2004	12	50·1	23·5 - 76·8	43	62·8	48·6 - 77·0	17	47·1	24·6 - 69·6	37	54·1	38·4 - 69·8	66	61·0 ^R	51·7 - 70·2	43	49·1 ^R	37·3 - 60·9
	2005-2009	18	51·4	29·7 - 73·0	38	57·8	42·3 - 73·4	22	57·4	34·1 - 80·6	28	62·5	46·1 - 78·9	63	59·9	47·9 - 71·9	43	62·7 ^R	50·9 - 74·5
Norway *																			
	1995-1999	5			17	76·5	57·0 - 96·0	10	50·0	21·2 - 78·8	10	40·1	12·2 - 67·9	24	66·7	48·4 - 85·1	18	50·0	28·0 - 72·1
	2000-2004	5			16	62·5	39·7 - 85·3	10	70·0	43·3 - 96·7	6			20	75·1	56·6 - 93·5	17	58·8	36·4 - 81·3
	2005-2009	7			11	73·4	48·8 - 98·0	5			6			18	74·9	53·9 - 95·8	11	58·2	32·4 - 84·1
Poland (Wroclaw)																			
	2000-2004				3			4			1			2			6		
	2005-2009	2			6			4			4			7			9		
Portugal *																			
	1998-1999				5			6			6			9			8		
	2000-2004	2			18	50·0	27·9 - 72·2	24	62·6	43·7 - 81·4	21	52·4	31·8 - 73·1	33	60·7	44·3 - 77·0	32	47·0 ^R	33·7 - 60·3
	2005-2009	1			15	48·1	25·9 - 70·3	15	66·8	45·7 - 87·9	21	67·3	48·0 - 86·6	26	58·1	40·5 - 75·6	26	63·0	46·1 - 79·9
Slovakia *																			
	2000-2004	1			11	27·3	3·6 - 51·0	10	40·0	12·2 - 67·9	13	61·6	36·4 - 86·7	12	33·4	8·8 - 58·0	23	52·2	32·4 - 72·0
	2005-2007	6			7			5			6			15	52·9	21·5 - 84·3	9		
Slovenia *																			
	1995-1999				1			3			3			4			3		
	2000-2004	1			4			1			5			7			4		
	2005-2009	2			6			4			3			3			12	81·6	59·4 - 100·0
Spanish registries																			
	1995-1999	8			15	40·0	16·6 - 63·5	4			11	45·5	18·1 - 72·9	16	50·1	26·7 - 73·5	22	45·5	25·4 - 65·7
	2000-2004	5			13	53·9	28·2 - 79·5	11	81·8	60·2 - 100·0	10	60·1	31·6 - 88·5	22	50·1	29·8 - 70·3	17	76·5	57·0 - 96·0
	2005-2009	4			14	58·8	36·5 - 81·2	10	55·7	28·5 - 82·9	18	68·3	47·9 - 88·6	31	60·4 ^R	48·0 - 72·7	15	58·1	35·5 - 80·7

Web-table 3: Acute myeloid leukaemia (ICCC3 Ib) - Five-year net survival (NS, %) by age group and sex: continent, country and calendar period of diagnosis

Calendar	Age group (years)												Sex					
	<1			1-4			5-9			10-14			Boys			Girls		
	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI	N	NS %	95% CI
Sweden *																		
1995-1999	8			23	73·9	56·4 - 91·4	8			11	72·7	47·8 - 97·7	20	<i>75·1</i>	<i>56·6 - 93·5</i>	30	<i>70·0</i>	<i>54·0 - 86·1</i>
2000-2004	14	71·5	49·7 - 93·2	20	50·0	28·9 - 71·1	9			13	38·5	14·0 - 62·9	26	<i>57·8</i>	<i>39·3 - 76·2</i>	30	<i>60·0</i>	<i>42·9 - 77·2</i>
2005-2009	6			22	68·0	48·7 - 87·2	6			14	53·6	29·8 - 77·5	23	<i>57·1</i>	<i>38·6 - 75·7</i>	25	<i>75·8</i>	<i>59·2 - 92·4</i>
Switzerland *																		
1995-1999	5			15	60·0	36·3 - 83·8	11	54·6	27·0 - 82·2	11	45·5	18·1 - 72·9	22	<i>54·6</i>	<i>34·5 - 74·8</i>	20	<i>55·1</i>	<i>34·0 - 76·1</i>
2000-2004	4			15	52·6	28·1 - 77·0	9			15	40·0	16·6 - 63·5	28	58·4^R	44·5 - 72·4	15	<i>45·8</i>	<i>21·5 - 70·0</i>
2005-2009	2			15	68·1	43·1 - 93·1	10	75·8	53·0 - 98·5	7			22	<i>75·1</i>	<i>58·1 - 92·1</i>	12	<i>74·1</i>	<i>50·0 - 98·2</i>
United Kingdom *																		
1995-1999	57	61·6	49·1 - 74·1	126	64·1	55·7 - 72·4	93	62·0	52·1 - 71·8	95	50·6	40·6 - 60·6	204	60·1	53·2 - 66·9	167	56·7	48·6 - 64·8
2000-2004	56	57·3	44·5 - 70·2	119	72·3	64·3 - 80·3	91	66·6	56·9 - 76·3	124	62·7	54·2 - 71·2	213	66·0	59·4 - 72·6	177	65·1	57·9 - 72·3
2005-2009	50	56·7	43·8 - 69·6	123	70·0	62·0 - 78·1	85	73·0	63·6 - 82·4	110	65·3	56·2 - 74·5	196	67·4	60·6 - 74·2	172	69·4	62·4 - 76·4
OCEANIA																		
Australian registries																		
1995-1999	14	35·8	13·1 - 58·5	41	48·8	33·8 - 63·8	41	56·1	41·2 - 71·0	29	58·7	41·1 - 76·2	61	50·9^R	41·1 - 60·6	64	55·4	43·5 - 67·4
2000-2004	23	60·4	40·7 - 80·1	54	74·0	62·4 - 85·6	39	71·8	57·9 - 85·7	54	70·4	58·4 - 82·5	94	72·5	62·7 - 82·2	76	69·4	59·3 - 79·6
2005-2009	21	76·1	58·1 - 94·1	47	85·5	75·6 - 95·4	20	59·3	41·4 - 77·2	41	63·2	49·1 - 77·3	65	74·2^R	65·7 - 82·8	64	67·4	56·7 - 78·1
New Zealand *																		
1995-1999	8			14	78·6	58·0 - 99·3	11	54·6	27·0 - 82·2	9			20	<i>55·1</i>	<i>34·0 - 76·1</i>	22	<i>81·9</i>	<i>66·2 - 97·6</i>
2000-2004	4			16	81·3	62·8 - 99·8	8			16	62·6	39·8 - 85·4	19	<i>73·7</i>	<i>54·5 - 93·0</i>	25	<i>64·1</i>	<i>45·7 - 82·5</i>
2005-2009	4			13	77·6	56·2 - 99·0	6			11	75·3	52·0 - 98·5	15	<i>64·2</i>	<i>42·0 - 86·3</i>	19	<i>83·2</i>	<i>66·2 - 100·0</i>